Protective Effects of Polydatin Against Bone and Joint Disorders: the and Evidence So Far
Overview
Affiliations
Polydatin is an active polyphenol displaying multifaceted benefits. Recently, growing studies have noticed its potential therapeutic effects on bone and joint disorders (BJDs). Therefore, this article reviews recent and progress on the protective role of polydatin against BJDs. An insight into the underlying mechanisms is also presented. It was found that polydatin could promote osteogenesis , and symptom improvements have been disclosed with animal models of osteoporosis, osteosarcoma, osteoarthritis and rheumatic arthritis. These beneficial effects obtained in laboratory could be mainly attributed to the bone metabolism-regulating, anti-inflammatory, antioxidative, apoptosis-regulating and autophagy-regulating functions of polydatin. However, studies on human subjects with BJDs that can lead to early identification of the clinical efficacy and adverse effects of polydatin have not been reported yet. Accordingly, this review serves as a starting point for pursuing clinical trials. Additionally, future emphasis should also be devoted to the low bioavailability and prompt metabolism nature of polydatin. In summary, well-designed clinical trials of polydatin in patients with BJD are in demand, and its pharmacokinetic nature must be taken into account.
Polydatin-Induced Shift of Redox Balance and Its Anti-Cancer Impact on Human Osteosarcoma Cells.
Cimmino A, Gioia M, Clementi M, Faraoni I, Marini S, Ciaccio C Curr Issues Mol Biol. 2025; 47(1).
PMID: 39852136 PMC: 11764470. DOI: 10.3390/cimb47010021.
Jo H, Baek C, Lee J, Hwang Y, Baek E, Song A Int J Mol Sci. 2024; 25(19).
PMID: 39408977 PMC: 11476456. DOI: 10.3390/ijms251910647.
Zhou C, Hu G, Li Y, Zheng S Int J Surg. 2024; 111(1):411-425.
PMID: 39248296 PMC: 11745762. DOI: 10.1097/JS9.0000000000002075.
Bagheri Bavandpouri F, Azizi A, Abbaszadeh F, Kiani A, Farzaei M, Mohammadi-Noori E Front Pharmacol. 2024; 15:1452989.
PMID: 39193334 PMC: 11347411. DOI: 10.3389/fphar.2024.1452989.
Hu L, Qian L, Sun A, Cai G, Gao Y, Yuan Y Front Pharmacol. 2023; 14:1253572.
PMID: 37849730 PMC: 10578493. DOI: 10.3389/fphar.2023.1253572.